-
Mashup Score: 44News Details - 1 day(s) ago
Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ES SENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3) 1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people
Source: www.novonordisk.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 81News Details - 8 day(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk
-
-
Mashup Score: 37News Details - 15 day(s) ago
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announce d the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SOUL top line N=9560 T2D + CVD or CKD Oral semaglutide 14% ⬇️ in MACE As part of standard of care, 49% of patients received SGLT2i at some point during the trial https://t.co/rtA0oXfGss
-
-
Mashup Score: 36News Details - 15 day(s) ago
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announce d the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SOUL top line N=9560 T2D + CVD or CKD Oral semaglutide 14% ⬇️ in MACE As part of standard of care, 49% of patients received SGLT2i at some point during the trial https://t.co/rtA0oXfGss
-
-
Mashup Score: 36News Details - 15 day(s) ago
Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announce d the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SOUL top line N=9560 T2D + CVD or CKD Oral semaglutide 14% ⬇️ in MACE As part of standard of care, 49% of patients received SGLT2i at some point during the trial https://t.co/rtA0oXfGss
-
-
Mashup Score: 81News Details - 15 day(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk
-
-
Mashup Score: 1Cell Therapy R&D Careers - 7 month(s) ago
Cell Therapy R&D Careers
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
Fortunately @novonordisk was watching the fallout on LinkedIn and had an opening in their cardiac cell therapy programme that I am now filling with a somewhat unique ability to contribute to the cells, the procedure & the patients https://t.co/t7vS0qBzR5 7/
-
-
Mashup Score: 0News Details - 8 month(s) ago
Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application (sNDA) for the indication of reducing ri sks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval is based on the
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
Whoops, looks like this is the direct link! https://t.co/jTpYsSQdj0
-
-
Mashup Score: 81News Details - 8 month(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: General Medicine News, CardiologistsTweet-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk
-
-
Mashup Score: 275News Details - 8 month(s) ago
Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW. The announcement today foll ows the decision to stop the trial early due to efficacy, which was announced on 10 October 2023, based on a recommendation from an Independent Data Monitoring Committee. The double-blind trial compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard of care for prevention of progression of kidney impairment and risk of kidney and
Source: www.novonordisk.comCategories: General Medicine News, General HCPsTweet-
Announcement from @novonordisk re the FLOW trial: Semaglutide reduced the risk of 50% decline in eGFR, kidney failure, or death due to kidney or cardiovascular disease by 24% Results to be presented this year by trial PI @VladoPerkovic & colleagues https://t.co/hZT4iPxRvl
-
We continue to have good news related to #GLP1RA 💥new data from the ESSENCE trial: Semaglutide 2.4 mg improves liver fibrosis & #MASH in RCT of 1200 pts! Confirmed by biopsy #CVPrev #cardiotwitter https://t.co/POTSxx5oxm https://t.co/D6xaYtBkzE